Alnylam (ALNY) Q2 2024: TTR Franchise Grows 37%, Helios B Data Sets Up Cardiomyopathy Launch
Alnylam’s Q2 marked a clear inflection, with strong TTR franchise growth and positive Helios B Phase 3 results positioning Vutrisiran for a potential first-line role in ATTR cardiomyopathy. Commercial execution and pipeline breadth reinforce the company’s transition toward a self-sustaining, top-tier biotech profile, even as expense scaling and competitive dynamics heighten the stakes for 2025 and beyond.
Summary
- TTR Franchise Momentum: ATTR portfolio strength and Helios B data set up a new commercial anchor.
- Pipeline Acceleration: RNAi platform advances with multiple late-stage and CNS programs now wholly owned.
- Expense Scale-Up: Launch prep and R&D investments rise as Alnylam targets sustainable profitability.
Business Overview
Alnylam Pharmaceuticals is a commercial-stage biotech focused on developing and marketing RNA interference (RNAi) therapeutics for rare and prevalent diseases. The company’s core revenue streams are its TTR franchise—driven by Onpattro and Amvuttra for hereditary ATTR amyloidosis—and its rare disease portfolio (Givlaari, Oxlumo). Collaboration and royalty income from partners like Regeneron and Novartis supplement product sales. Alnylam’s pipeline spans liver, CNS, muscle, and adipose targets, with a strategy to double clinical programs by 2025.
Performance Analysis
Alnylam delivered a robust quarter, with net product revenue up 34% year-over-year, propelled by the TTR franchise’s 37% growth and rare disease portfolio expansion. The TTR business, now approaching 5,000 patients globally, benefited from rapid Amvuttra uptake—especially in the U.S., where 90% of TTR patients have switched to Amvuttra, and international markets saw similar momentum. Rare disease products contributed $103 million, with Oxlumo up 68% year-over-year and Givlaari up 7%.
Collaboration revenue surged, driven by a one-time recognition of $185 million from a Regeneron agreement modification, while royalty revenue tripled on growing Novartis Leqvio sales. Gross margin improved to 84%, but management expects some normalization as Ambutra royalties increase. Operating income swung to a positive $138 million, a $292 million improvement, and cash climbed to $2.6 billion, supporting the path to self-sustainability.
- Segment Outperformance: TTR franchise delivered $307 million, up 16% sequentially and 37% year-over-year, now the clear growth engine.
- Rare Disease Growth: Givlaari and Oxlumo combined for 25% year-over-year growth, with Oxlumo U.S. demand especially strong.
- Expense Scaling: R&D and SG&A rose 14% and 21% respectively as pipeline advances and launch prep intensified.
Alnylam raised full-year revenue guidance by 11% at the midpoint, reflecting commercial momentum and confidence in the upcoming ATTR cardiomyopathy launch, while also increasing expense guidance to support pipeline and launch investments.
Executive Commentary
"The major highlight of Q2 was our announcement of positive top-line results in the Helios B phase 3 study of Vutrisiran in ATTR cardiomyopathy, showing that Vutrisiran improved cardiovascular outcomes, including a 35% to 36% mortality benefit compared to placebo, and demonstrated encouraging safety. These results reflect the true power of the RNAi mechanism of action, supporting what we believe to be a highly differentiated therapeutic profile and positioned Vutrisiran as the new standard of care in ATTR cardiomyopathy, assuming regulatory approval."
Yvonne Greenstreet, Chief Executive Officer
"We are increasing our net product revenue guidance from a range of 1.4 to 1.5 billion to a range of 1.575 to 1.65 billion representing an 11% increase from the midpoint of the prior to the updated guidance. The primary driver of the increased guidance is the ongoing strength of performance in our hereditary ATTR polyneuropathy franchise."
Jeff Poulton, Chief Financial Officer
Strategic Positioning
1. Helios B Data as Commercial Catalyst
Positive Phase 3 Helios B results for Vutrisiran in ATTR cardiomyopathy are transformative, with statistically significant reductions in mortality and cardiovascular events. Management positions Vutrisiran as a potential first-line standard of care, citing physician enthusiasm and robust efficacy across both monotherapy and add-on subgroups. The ATTR-CM population is estimated at ten times the size of the current polyneuropathy segment, setting up a multi-year growth runway if approved.
2. Commercial Execution and Market Access
Alnylam’s commercial infrastructure is a core asset, enabling rapid patient onboarding and high U.S. penetration for Amvuttra. The company leverages a physician-administered Part B reimbursement model, which management argues provides lower patient copays and faster access than oral competitors. Internationally, Alnylam maintains >90% market share in price-sensitive markets, demonstrating payer negotiation strength.
3. Pipeline Expansion and Portfolio Ownership
Pipeline breadth is accelerating, with nine proprietary INDs targeted by end-2025 and a doubling of clinical programs. Notably, the Regeneron opt-out gives Alnylam full ownership of Mivalceran (CNS), with Phase 2 studies in cerebral amyloid angiopathy and Alzheimer’s disease planned. Investment in CNS and cardiovascular programs signals a push beyond rare diseases into broader indications, increasing both opportunity and complexity.
4. Capital Allocation and Financial Discipline
Alnylam’s cash position of $2.6 billion supports pipeline advancement and launch readiness. Management increased R&D and SG&A guidance to reflect both the Regeneron opt-out (requiring higher internal spend) and ATTR-CM launch preparation. The company remains committed to achieving a 40%+ revenue CAGR through 2025 and sustainable non-GAAP operating income, but the expense ramp will test execution discipline as growth investments accelerate.
5. Competitive and Regulatory Landscape
Management anticipates a dynamic competitive environment, particularly as new therapies for ATTR-CM emerge and payer scrutiny intensifies. Alnylam’s emphasis on rapid knockdown, quarterly dosing, and payer access are positioned as differentiators. The upcoming ESC Congress and FDA filing (using a priority review voucher) are key regulatory milestones that will shape label, positioning, and uptake trajectory.
Key Considerations
This quarter’s results reflect a pivotal moment for Alnylam, with execution, pipeline, and commercial readiness converging ahead of a major launch. Investors should weigh:
Key Considerations:
- ATTR-CM Launch Readiness: Helios B data and market preparation set the stage for a high-impact 2025 launch, but execution risk remains as the company scales sales and support teams.
- Expense Leverage vs. Profitability: Increased R&D and SG&A spending will pressure near-term margins, even as top-line growth accelerates.
- Pipeline Self-Sufficiency: Regeneron’s opt-out hands Alnylam global rights to Mivalceran, increasing both potential upside and internal resource demands.
- Reimbursement and Payer Dynamics: Part B coverage and copay minimization are strategic levers, but future IRA-driven Medicare changes and ICER cost-effectiveness reviews could impact pricing power.
- Competitive Dynamics: New entrants and evolving standards in ATTR and rare disease markets will test Alnylam’s differentiation and market share resilience.
Risks
Regulatory and launch execution risk is elevated as Alnylam prepares the Vutrisiran ATTR-CM filing and potential 2025 launch. Expense scaling could outpace revenue if uptake lags, particularly given the increased R&D and SG&A guidance. Payer pushback, competitive entrants, and evolving Medicare rules (including IRA implications) may affect pricing and access. The company’s transition to broader indications increases operational complexity and long-term uncertainty.
Forward Outlook
For Q3, Alnylam guided to:
- Continued strong TTR franchise growth, with U.S. and international demand momentum.
- Ongoing rare disease franchise expansion, particularly in Oxlumo and Givlaari.
For full-year 2024, management raised guidance:
- Net product revenue: $1.575 to $1.65 billion (up 11% at midpoint).
- Collaboration/royalty revenue: $575 to $650 million.
- Combined R&D and SG&A: $1.775 to $1.875 billion (reflecting pipeline and launch investment).
Management highlighted several factors that will drive the outlook:
- Detailed Helios B data at ESC Congress (August 30) and TTR Investor Day (October 9) as catalysts.
- Supplemental NDA filing for Vutrisiran in ATTR-CM and use of a priority review voucher to accelerate approval.
- Three new IND filings, three trial initiations (including TTR-SC04 and CNS programs), and interim data from the ALN-APP Alzheimer’s study.
Takeaways
Alnylam’s Q2 performance and pipeline progress reinforce its evolution from rare disease specialist to diversified RNAi leader.
- TTR Franchise as Growth Engine: Robust demand and Helios B data position Vutrisiran for a leading role in the much larger ATTR-CM market, anchoring future revenue growth.
- Pipeline and Portfolio Expansion: Full ownership of CNS assets and new late-stage trials diversify opportunity, but require disciplined investment and execution.
- Execution Watchpoints for 2025: Investors should monitor launch uptake, expense leverage, and payer dynamics as the company targets sustainable profitability and broader indications.
Conclusion
Alnylam’s second quarter marks a strategic turning point, with commercial momentum, pipeline breadth, and Helios B data setting up a high-stakes 2025. Execution on launch, expense control, and payer access will determine whether Alnylam delivers on its ambition to become a top-tier, self-sustaining biotech.
Industry Read-Through
Alnylam’s results highlight the commercial and clinical inflection in RNAi therapeutics, with the ATTR-CM opportunity underscoring the potential for RNAi to move from rare to more prevalent diseases. Success in payer negotiation and Part B access sets a benchmark for other specialty pharma companies navigating the U.S. reimbursement landscape, especially as IRA-driven changes reshape Medicare economics. Pipeline expansion into CNS and broader indications signals that RNAi platforms are maturing beyond niche applications, raising the bar for both innovation and operational scale across the biotech sector. Competitive intensity in ATTR and rare disease markets will likely increase, with differentiation hinging on efficacy, dosing convenience, and payer alignment.